Cinctive Capital Management’s Cogent Biosciences COGT Stock Holding History

Cinctive Capital Management’s Portfolio COGT Stock Details COGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.65M	Sell	42,703 -26,058	-38%	-$912K	0.06%	282
2026 Q1	$2.65M	Buy	68,761 +24,096	+54%	+$890K	0.17%	182
2025 Q4	$1.59M	Sell	44,665 -66,393	-60%	-$1.87M	0.09%	232
2025 Q3	$1.59M	Buy	+111,058	New	+$1.32M	0.08%	271
2025 Q1	–	Sell	-40,643	Closed	-$317K	–	345
2024 Q4	$317K	Sell	40,643 -289,776	-88%	-$2.89M	0.02%	331
2024 Q3	$3.57M	Buy	330,419 +157,969	+92%	+$1.54M	0.19%	172
2024 Q2	$1.45M	Buy	172,450 +26,936	+19%	+$204K	0.07%	273
2024 Q1	$978K	Buy	+145,514	New	+$900K	0.05%	294

Other funds holding COGT

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jupiter Topco New York $245B AUM

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Cinctive Capital Management's COGT Position: Q2 2026 in Review

Cinctive Capital Management reduced its Cogent Biosciences (COGT) stake by 38% in Q2 2026, selling an estimated $912K and leaving 42,703 shares worth $1.65M. The position accounts for 0.06% of the portfolio, ranked #282.

Cinctive Capital Management first reported a position in COGT in Q1 2024 and has held it in 8 quarters since. The position peaked at $3.57M in Q3 2024. 324 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

Cinctive Capital Management held 42,703 shares of Cogent Biosciences worth $1.65M as of Q2 2026.
Cinctive Capital Management sold 26,058 Cogent Biosciences shares in Q2 2026, an estimated $912K.
Cogent Biosciences made up 0.06% of Cinctive Capital Management's portfolio in Q2 2026, its #282 holding.
Cinctive Capital Management first reported a position in Cogent Biosciences in Q1 2024 and has held it in 8 quarters since.
Cinctive Capital Management's Cogent Biosciences position peaked at $3.57M in Q3 2024.
324 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on Cinctive Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.